Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

GRECO-1: Phase I/II, Randomized, Placebo-Controlled Study of Stereotactic Body Radiation Therapy (SBRT) and GC4711 for Centrally Located or Large, Node-Negative Non-Small Cell Lung Cancer (NSCLC)

NCT04476797 is registered in ClinicalTrials.gov with Galera Therapeutics, Inc. as lead sponsor.

NCT NCT04476797
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04476797 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
GRECO-1: Phase I/II, Randomized, Placebo-Controlled Study of Stereotactic Body Radiation Therapy (SBRT) and GC4711 for Centrally Located or Large, Node-Negative Non-Small Cell Lung Cancer (NSCLC)
Lead sponsor
Galera Therapeutics, Inc.
Phase
Phase 1/2
Overall status
Terminated
Start date
October 18, 2020
Completion date
November 28, 2023
Enrollment
47 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

non-metastatic, nsclc, sbrt